Details for Patent: 9,283,219
✉ Email this page to a colleague
Which drugs does patent 9,283,219 protect, and when does it expire?
Patent 9,283,219 protects KYNMOBI and is included in one NDA.
This patent has thirty-nine patent family members in twenty countries.
Summary for Patent: 9,283,219
| Title: | Sublingual films |
| Abstract: | The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith. |
| Inventor(s): | Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons |
| Assignee: | Sunovion CNS Development Canada ULC , Sumitomo Pharma America Inc |
| Application Number: | US14/478,975 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 9,283,219
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-002 | May 21, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-004 | May 21, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-005 | May 21, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,283,219
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011343429 | ⤷ Start Trial | |||
| Australia | 2017200331 | ⤷ Start Trial | |||
| Australia | 2019200138 | ⤷ Start Trial | |||
| Brazil | 112013015204 | ⤷ Start Trial | |||
| Canada | 2821756 | ⤷ Start Trial | |||
| Canada | 3115370 | ⤷ Start Trial | |||
| Canada | 3115378 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
